This inventor holds 3 USPTO granted patents and 1 EPO patent. Top assignees: Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus, Qiagen Gmbh, Chemotherapeutisches Forschunginstitut Georg Speyer-Haus Zu Frankfurt. Active years: 1997-1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 3 
2 out of 269 
1 out of 1 Years Active: 1997-1999
Title: **Innovative Contributions of Michalina Adamski in HIV Research**
Introduction
Michalina Adamski, based in Frankfurt-am-Main, DE, is a prominent inventor recognized for her groundbreaking work in the field of HIV research. With a total of three patents to her name, her contributions significantly impact therapeutic approaches to combat HIV infections.
Latest Patents
Adamski’s latest patents focus on innovative solutions for protection against HIV infections. Among these are a vaccine specifically designed to provide protection against HIV, a process for its preparation, and therapeutic agents for treatment following HIV infections. Another notable patent involves the differentiation between HIV-2.ALT type infections and prototype HIV-2 infections, marking substantial advancements in understanding HIV-2 virus variants.
Her inventions describe the virus HIV-2.D205 and its variants, distinguished from the prototype HIV-2.ROD by nucleotide sequence homology of less than 77%. This includes proteins and nucleic acids of HIV-2.D205 and its variants, intended for use in vaccines, immunotherapy, animal models, and differential diagnostics. Additionally, her patents cover the processes involved in preparing these vaccines, therapeutic agents, and diagnostic tools.
Career Highlights
Throughout her career, Michalina Adamski has worked with reputable organizations, including Qiagen GmbH and the Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus. Her research in these institutions has fostered innovative developments in diagnostic and therapeutic practices for HIV infections.
Collaborations
Adamski has collaborated with esteemed colleagues, such as Ursula Dietrich and Hagen von Briesen. These partnerships have enhanced the impact of her research and facilitated the advancement of innovative solutions in HIV treatment.
Conclusion
In summary, Michalina Adamski stands as a leading figure in HIV research, with her patented innovations contributing to significant progress in the fight against this virus. Her work not only inspires the scientific community but also brings hope for effective therapeutic strategies to combat HIV infections.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile